ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Basic/Clinical Science Session

Overflow by Gliflozins: Mechanisms and Consequences of the Off-Target Effects of SGLT2 Inhibitors

October 23, 2020 | 10:30 AM - 12:30 PM

Location: Simulive

Session Description

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are new treatments approved by the US Food and Drug Administration for individuals with diabetic kidney disease. Although a primary mechanism of action is known, several additional renal and extrarenal perturbations have been discovered. The nature and contribution of these "off-target" effects are being elucidated. This session explores these effects and whether they play an instrumental or confounding role in the positive effects of SGLT2 inhibitors on renal and cardiovascular disease.

Learning Objective(s)

  • Identify the mechanisms and consequences of sodium-hydrogen exchanger 3 (NHE3) inhibition by SGLT2 inhibitors
  • Discuss the effects of SGLT2 inhibitors on divalent cation homeostasis, including calcium and magnesium
  • Elucidate the potential role of uric acid excretion for observed benefits of SGLT2 inhibitors on kidney and cardiovascular disease
  • Describe the direct effects of SGLT2 inhibitors on mitochondria and their downstream consequences

Learning Pathway(s)

  • Cell and Transport Physiology
  • Diabetes and Metabolism

Moderators

  • Carolyn M. Ecelbarger, PhD
  • Carol A. Pollock, MD, PhD

Presentations

  • Role of Sodium-Hydrogen Exchanger 3 (NHE3) Inhibition and Sodium-Glucose Cotransporter 2 (SGLT2)-Mediated NHE3 Inhibition in the Diabetic Kidney
    10:30 AM - 11:00 AM
    Alicia A. McDonough, PhD
  • Mechanisms of SGLT2 Inhibitor Nephroprotection Beyond Glomerular Hemodynamics
    11:00 AM - 11:30 AM
    Richard E. Gilbert, MD, PhD, FASN
  • The Role of Uric Acid in Cardiorenal Benefits of SGLT2 Inhibition
    11:30 AM - 12:00 PM
    Clifford J. Bailey, PhD 
  • Alterations in Mitochondrial Function by SGLT2 Inhibitors
    12:00 PM - 12:30 PM
    Tetsuji Miura, MD, PhD